Status Epilepticus in Neonates

Arushi Gahlot Saini 1 Kollencheri Puthenveettil Vinayan 2

1 Pediatric Neurology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India
2 Division of Pediatric Neurology, Department of Neurology, Amrita Institute of Medical Sciences, Amrita University, Cochin, Kerala, India

Address for correspondence Kollencheri Puthenveettil Vinayan, Division of Pediatric Neurology, Department of Neurology, Amrita Institute of Medical Sciences, Cochin, 682041, Kerala, India (e-mail: vinayankp@aims.amrita.edu).

Int J Epilepsy 2018;5:2–8

Seizures are a reflection of acute brain injury in the neonatal period, and status epilepticus reflects a state of high seizure burden. Neonatal status epilepticus has been reported in 8 to 43% of newborns with seizures. There is no separate definition for neonatal status epilepticus, and it has been commonly defined as a continuous seizure lasting at least 30 minutes and/or a series of seizures whose total duration exceeds 50% of a given episode. The causes of status epilepticus in the neonatal period mirror the causes of neonatal seizures. It is symptomatic, usually associated with hypoxic–ischemic encephalopathy, inherited metabolic disorders, infections, and cerebral hemorrhage.

Management guidelines are not separately outlined for neonatal status epilepticus and are commonly derived from the recommendations for neonatal and infantile seizures. The presence of neonatal status epilepticus significantly increases the odds for development of cerebral palsy, global developmental delay, and epilepsy later in life. Further research is needed into the role of current antiepileptic drugs in causing neuronal injury and use of neuroprotective agents during neonatal status epilepticus.

Abstract

Seizures are a reflection of acute brain injury in the neonatal period, and status epilepticus reflects a state of high seizure burden. Neonatal status epilepticus has been reported in 8 to 43% of newborns with seizures. There is no separate definition for neonatal status epilepticus, and it has been commonly defined as a continuous seizure lasting at least 30 minutes and/or a series of seizures whose total duration exceeds 50% of a given episode. The causes of status epilepticus in the neonatal period mirror the causes of neonatal seizures. It is symptomatic, usually associated with hypoxic–ischemic encephalopathy, inherited metabolic disorders, infections, and cerebral hemorrhage.

Management guidelines are not separately outlined for neonatal status epilepticus and are commonly derived from the recommendations for neonatal and infantile seizures. The presence of neonatal status epilepticus significantly increases the odds for development of cerebral palsy, global developmental delay, and epilepsy later in life. Further research is needed into the role of current antiepileptic drugs in causing neuronal injury and use of neuroprotective agents during neonatal status epilepticus.

Keywords

► neonatal seizures
► neonatal status epilepticus
► status epilepticus
► antiepileptic
► brain injury

Introduction

Seizures are the most common reflection of an acute brain injury in the neonatal period. The first 4 weeks of life (neonatal period) are at the highest risk for seizures secondary to an underlying predisposition of the immature brain as well as the nature of the inciting injury. Seizures occur in 1 to 3.5 per 1,000 births.1 The neonatal seizure continuum ranges from isolated events to recurrent seizures and status epilepticus. Neonatal status epilepticus (NSE) reflects a high seizure burden state and is associated with worse neurologic outcomes compared with recurrent seizures.2

NSE is distinct from status epilepticus in children and adults in definition, etiopathogenesis, electroencephalographic (EEG) features, management, and outcomes. It resembles neonatal seizures more than it does status epilepticus at later ages. However, management recommendations are currently based on those for children and adults with some age-specific modifications. We discuss here the unique features of NSE and discuss the current recommendations for its diagnosis and management.

The Unique Neurobiology of a Neonatal Brain

Neonatal seizure and status epilepticus are unique as the neonatal brain differs in both structure and physiologic functioning from the brains of children and adults. The neonatal brain has a distinct predilection for neuronal excitation and subsequent seizures. Several probable neurobiological mechanisms have been put forward to explain this increased susceptibility:

• There is an overexpression of glutamate (the major excitatory neurotransmitter of the central nervous system) as well as altered expression of its N-methyl-D-aspartate (NMDA) (overexpression of NR2B subunits) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors (lack of GluR2 subunit).3
• There is reduction in γ-aminobutyric acid (GABA) (the major inhibitory neurotransmitter in the central nervous system), its receptor expression, and alteration in its distribution (overexpression of α4 and α2 subunits compared with α1) leading to benzodiazepine resistance.4
• There is underexpression of KCC2 (pumps Cl− ions out) and overexpression of NKCC1 (pumps Cl− in) channels on the immature neonatal neurons resulting in a higher intracellular Cl− ion concentrations. GABA-agonist medications such as phenobarbitone and benzodiazepines (meant to cause neuronal hyperpolarization in a mature brain) thus result in paradoxical depolarization in the immature neurons due to the net efflux of Cl− ions.  

• This Cl− ion gradient matures in a caudo-rostral direction during development. This maturational gradient may lead to inhibition of motor neurons in the spinal cord and brainstem while depolarizing the cortical neurons with the use of GABA-agonists, resulting in electromechanical dissociation with phenobarbitone and midazolam use.

• In the neonatal brain, although the basic organization of the cerebral cortex remains the same as in older children, the dendritic arborization, connections, and synaptic stabilizations are incomplete and the myelination is immature. This prevents rapid, well-organized spread of epileptic discharges in the brain and absence of the classic type of generalized, tonic-clonic status epilepticus in neonates. Additionally, the electroclinical dissociation and presence of subtle nonobtrusive signs such as autonomic variations, apnea, and oculomotor or oral-buccal-lingual movements in neonatal seizures suggest the possibility of a subcortical generator rather than the overlying cerebral cortex as in older children and adults.  

• Based on serial electrographic maturational changes during status epilepticus during the first 6 months of life, it has been suggested that infants older than 2 months start exhibiting electrographic features similar to those of status epilepticus seen in older children such as presence of prolonged seizures or partial seizures with one focus and secondary generalization. However, the electrographic features of NSE in infants younger than 2 months are usually distinct as described above.

Definitions

The conventional definition describes status epilepticus in children and adults as “any continuous seizure activity lasting ≥30 minutes or ≥2 seizures without regaining baseline mental status in between the events.” An operational definition of status epilepticus proposes “any continuous clinical seizure activity lasting for ≥ 5 minutes or ≥ 2 seizures without regaining baseline mental status in between.” Recently, the International League Against Epilepsy (ILAE) has revised the definition of status epilepticus as “a condition resulting either from failure of the mechanisms responsible for seizure termination or from the initiation of mechanisms, which lead to abnormally, prolonged seizures (after time point t1), and long-term consequences (after time-point t2), including neuronal death, neuronal injury, and alteration of neuronal networks, depending on the type and duration of seizures.” Duration longer than 5 minutes has been considered “prolonged” and longer than 30 minutes has been associated with sequelae for generalized tonic clonic seizures.

The latest ILAE report suggests classifying neonatal seizures according to the same descriptors as other seizures, rather than a separate entity. NSE has not been as clearly defined although the 5-minute duration seems more logical as majority of neonatal seizures do not last > 2 to 3 minutes. It has been variably defined as a “continuous seizure activity lasting > 30 minutes and/or a series of seizures whose total duration exceeds 50% of a given epoch.” Given the worse outcomes associated with NSE and the need for prompt treatment, a clinical definition to treat “all frequent or prolonged seizures ≥ 5 minutes in duration as status epilepticus” has also been used. This variability in defining NSE has led to inconsistent estimates (8–43%) of the burden of NSE in newborns with seizures. The challenges in defining neonatal seizures and status epilepticus are:

• The seizure semiology, clinical and EEG characteristics in neonates are different compared with older children. Most seizures in the neonates are either subtle, multifocal, migratory, or rarely fully generalized whereas majority of the current literature of status epilepticus is based on well-organized, generalized tonic-clonic status.

• As the average duration of neonatal seizures ranges from 1 to 5 minutes, and solitary prolonged seizures are rare; hence, a 30-minute definition would underdiagnose NSE. Neonates with seizures and status are commonly critically ill and encephalopathic, thus making the recognition of baseline mental status or a return to it difficult.

• Nearly 80 to 90% of electrographic seizures lack a clinical correlate and would not be identified without continuous EEG. Further, anticonvulsant administration may terminate clinically evident seizures whereas electrographic-only seizures may persist resulting in electroclinical uncoupling or dissociation.

• Defining NSE as any electrographic recording with seizure activity noted over a certain (most commonly > 50%) proportion of the length of the recording time would not be useful and difficult to apply in resource-limited settings where routine continuous EEG monitoring is not available and interictal recording times vary. Also, there is a clear lack of evidence to support any particular threshold to designate a high seizure burden as SE.

Etiology

In general, the causes of NSE mirror the causes of neonatal seizures that are most often symptomatic markers of brain injury. The most common cause of recurrent seizures in the newborn is hypoxic ischemic encephalopathy (50–60%). These seizures are noted within the first 12 to 24 hours of life, associated with encephalopathy, and are subtle and multifocal in nature. The next most common cause is vascular, either arterial or venous strokes, resulting in focal seizures after 24 hours of age and associated with minimal baseline encephalopathy. An important cause of NSE is intracranial hemorrhage, isolated or more commonly associated with hypoxic ischemic encephalopathy or stroke. Intraventricular hemorrhage, in particular, may cause subtle seizures in the preterm neonate. Other causes include central nervous...
system infections, congenital malformations, acute or inherited metabolic disorders, local anesthetic intoxication, drug withdrawal, and hereditary epilepsies. Although acute transient metabolic disorders such as hypoglycemia, hypocalcemia, hypomagnesemia, or hypophosphatemia cause recurrent seizures more than NSE, these must be recognized early as specific therapy is warranted in these cases. Neonatal seizures need to be differentiated from neonatal-onset inherited epilepsies. Inborn errors of metabolism should be suspected in the absence of an acute insult or structural cause when seizures are accompanied by encephalopathy and when seizures are refractory to the standard anticonvulsants (Table 1).

### Approach to Neonatal Status Epilepticus

The diagnosis of neonatal seizures is largely clinical in routine practice, and a detailed approach has been described elsewhere. Nevertheless, in a neonate with suspected or confirmed status epilepticus, five questions need to be asked:

- **Are the clinical events seizures or mimics?** The answer to this question often requires an EEG correlate of the ictal activity. Whereas focal clonic and tonic seizures have a good EEG correlate, subtle and myoclonic seizures correlate poorly with the EEG. Epileptic movements in the neonates and infants include generalized myoclonic jerks, myoclonic jerks of the diaphragm leading to frequent hiccups (glycine encephalopathy), clonic limb jerking, tongue thrusting, focal tonic posturing when associated with autonomic features, and tonic eye deviation and epileptic spasms. Movements that are less likely to be epileptic without further investigation include cycling, pedaling or thrashing of limbs, side-to-side movements of the head, sucking, lip puckering, grimacing, tongue protrusion, blinking without tonic eye deviation, roving eye movements, nystagmus, and generalized tonic stiffening.

- **Is there a clinical or investigative evidence for a preexisting neurologic condition in the neonate such as malformations, genetic disorders, or remote structural injuries?** Clinical clues to an underlying predisposition include presence of microcephaly, dysmorphic features, or genetic or neuroimaging abnormality.

- **Are seizures provoked or unprovoked?** Majority of neonatal seizures are acute symptomatic seizures secondary to a hypoxic, ischemic, infective, vascular or metabolic disturbance, and need correction of underlying abnormality besides antiepileptic drugs. Unprovoked seizures associated with genetically determined early-onset epileptic encephalopathies need specific investigations and therapy.

- **Are the seizures themselves associated with an increased risk of brain injury and subsequent poorer neurodevelopmental outcome?** NSE has been associated with a lower full-scale intelligent quotient and increased risk of subsequent epilepsy.

- **Does the antiseizure treatment outweigh the risks of ongoing seizures?** The answer to this question is particularly difficult as the short- and long-term side effects of antiepileptic drugs are not known in NSE.

The clinical presentations of recurrent neonatal seizures and status epilepticus can be variable and many are subclinical. Hence, clinical identification alone may be unreliable and insufficient. Investigations in NSE are limited, and seizure control takes a priority as ongoing seizures have been shown to cause long-term neuronal loss and cognitive impact in animal studies. Nevertheless, appropriate blood and cerebrospinal fluid investigations to rule out underlying metabolic abnormalities or infection and neuroimaging are essential.

### Table 1: Common causes for recurrent neonatal seizures and neonatal status epilepticus

<table>
<thead>
<tr>
<th>Cause</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypoxic–ischemic encephalopathy</td>
</tr>
<tr>
<td>Intracerebral hemorrhage</td>
</tr>
<tr>
<td>Ischemic stroke</td>
</tr>
<tr>
<td>Cerebral venous thrombosis</td>
</tr>
<tr>
<td>Central nervous system infections</td>
</tr>
<tr>
<td>Acquired metabolic insults</td>
</tr>
<tr>
<td>Hypoglycemia, hypocalcemia, hypomagnesemia, hypophosphatemia, hyperbilirubinemia</td>
</tr>
<tr>
<td>Narcoic withdrawal</td>
</tr>
<tr>
<td>Trauma</td>
</tr>
<tr>
<td>Brain malformation</td>
</tr>
<tr>
<td>Neonatal epilepsies (genetic)</td>
</tr>
<tr>
<td>Benign familial neonatal epilepsy, early myoclonic epileptic encephalopathy</td>
</tr>
<tr>
<td>Inborn errors of metabolism (genetic and in need of specific dietary or cofactor therapy)</td>
</tr>
<tr>
<td>Pyridoxine dependent epilepsy, folinic acid responsive seizures, nonketotic hyperglycinemia, sulfite oxidase deficiency, molybdenum cofactor deficiency, holocarboxylase, biotinidase deficiency, organic acidurias, Menkes disease, peroxisomal disorders, hereditary fructose intolerance, fructose 1,6-diphosphate deficiency, urea cycle defects</td>
</tr>
</tbody>
</table>
investigations. Specifically, a lumbar puncture analysis also aids in the diagnosis in case of glucose transporter defects (with a cerebrospinal fluid-to-plasma glucose ratio < 0.35), mitochondrial cytopathies (elevated lactate), and glycine encephalopathy (with a cerebrospinal fluid-to-plasma glycine ratio > 0.08). Correct identification, evolution, and prognosis are enhanced by the use of EEG or amplitude-integrated EEG (aEEG) monitoring of high-risk infants. Although continuous EEG monitoring and intensive care is recommended in all cases of status epilepticus, the same may not be feasible in resource-limited emergency settings.\textsuperscript{33,34} The American Clinical Neurophysiology Society's guideline on continuous EEG monitoring in neonates states that "conventional video-EEG monitoring is the gold standard for neonatal seizure detection and quantification and should be used whenever available for seizure detection and differential diagnosis of abnormal appearing, paroxysmal clinical events. It is the ideal tool to measure the exact number and duration of seizures, their site(s) of onset and spatial patterns of migration."\textsuperscript{35} However, in resource-limited settings, at least a routine EEG is warranted in all cases of recurrent neonatal seizures, in cases of persisting neonatal encephalopathy with or without anticonvulsant or neuromuscular blockade to rule out epileptic encephalopathies, subclinical or non-convulsive seizures. The neonatal interictal EEG recording should last minimum of 1 hour to capture all stages of sleep. A reduced-montage EEG recording, aEEG, is gaining popularity in many neonatal intensive care units due to its simplified display of one or two channels of time-compressed, processed EEG signal on a semilogarithmic scale. The interpretation can be done by the treating physician/neurologist at the bedside by pattern identification and is enhanced by concurrent display of the raw signal or multichannel EEG. Although the aEEG background patterns have been shown to have predictive value for neonates with encephalopathy, including hypoxic ischemic encephalopathy, its use for detection of seizures is controversial due to its very low sensitivity.

As in older children and adults, NSE is a life-threatening condition requiring rapid treatment and prevention of neuronal death as well as secondary injury.\textsuperscript{36} Time is the key in the management of status epilepticus because as many as 43% of neonatal seizures may progress into status epilepticus. Seizures become more difficult to treat the longer they last, and a higher seizure burden portends worse outcomes.\textsuperscript{37} The management of NSE begins with maintenance of airway, breathing and circulation; assessment of the etiological cause; and simultaneous use of anticonvulsant drugs, especially if the baby is sick or encephalopathic (\textit{\textsuperscript{\textcircled{A}}}Fig. 1). In the majority of NSEs, the underlying cause of symptomatic seizures such as hypoxic-ischemic encephalopathy, stroke or hemorrhage, and infections need to be dealt with appropriate measures simultaneously. A trial of intravenous glucose and calcium may be considered in neonates with seizure at the onset and simultaneous samples to be collected for evaluation of hypoglycemia, hypocalcemia, and hypomagnesemia, especially in absence of history of hypoxic-ischemic injury. Evidence-based guidelines for optimal antiepileptic management of NSE are currently not available. The current anticonvulsant drugs are effective in nearly 50% patients as a single agent and in 60 to 70% patients with multiple agents.\textsuperscript{38} Phenobarbital remains the drug of choice as first-line agent (dose 15–20 mg/kg loading dose by intravenous route that may be repeated and is followed by maintenance dosages of 3–5 mg/kg/day) to treat recurrent neonatal seizures and status epilepticus although concerns have been raised over the risk of neuronal apoptosis with increasing serum concentrations of the drug.\textsuperscript{39} The second-line agent is either phenytoin or fosphenytoin (dose 15–20 mg/kg loading dose by intravenous route followed by maintenance dosages of 5–8 mg/kg/day). Benzodiazepines are commonly used next. Intravenous lorazepam (loading dose of 0.05–0.10 mg/kg in 5 minutes) is used intermittently with a rapid response, half-life of 40 hours, and minimal side effects in neonates. Alternatively, midazolam infusion (incremental dose of 0.1–0.5 mg/kg/h, maximum up to 1 mg/kg/h) is used along with intensive monitoring for respiratory depression.\textsuperscript{40} By this time, it is prudent to administer empiric therapy and/or exclude treatable metabolic disorders such as pyridoxine dependent epilepsy (dose of 100 mg intravenous pyridoxine during EEG monitoring followed by 30 mg/kg/day divided into two to three doses by oral or intravenous route over 3 consecutive days), folinic-acid responsive seizures (2.5 mg intravenous or oral folinic acid in a dose of 3–5 mg/kg/day in two to three divided doses over 3 days), and biotinidase deficiency (oral biotin in a dose of 5–10 mg/day). In persisting seizures, a trial of pyridoxal-5’-phosphate (dose of 30–50 mg/kg/day in three to four divided doses over 3 days) is warranted.\textsuperscript{41} Also, continuous EEG monitoring should be considered at this point as the subclinical seizures may persist. Newer antiepileptic drugs such as levetiracetam (loading dose of 20–30 mg/kg followed by initial maintenance dose of 5–10 mg/kg/day, which may be increased if required), lidocaine, and oral topiramate are the next line agents depending on the feasibility and availability of the drugs. Although limited safety and efficacy data are available on the use of levetiracetam in neonates, its use is increasing due to the easy availability of intravenous formulation and favorable side effect profile among older children and adults.\textsuperscript{42} The drug has received approval of the Food and Drug Administration (FDA) for use in infants 1 month of age and older in 2011. Seizure control within 1 hour has been achieved in up to 86% neonates treated with intravenous levetiracetam.\textsuperscript{43} Additionally, levetiracetam is a good choice in neonates with cardiac or liver dysfunction or acute brain injury. Levetiracetam does not enhance neuronal apoptosis in the developing brain and might have neuroprotective effects.\textsuperscript{44} Drugs rarely used for NSE include valproate, paraldehyde, vigabatrin, and carbamazepine.\textsuperscript{45} Therapeutic hypothermia has emerged as a useful neuroprotective strategy for newborns with mild to moderate hypoxic ischemic encephalopathy and seizures, which show a significantly reduced seizure burden.\textsuperscript{46} The study on the use of bumetanide as an adjuvant to phenobarbital for the treatment of neonatal seizures posthypoxic ischemic encephalopathy (NEMO [treatment of NEonatal seizure using Medication Off-patent] trial) demonstrated serious side effects including hearing loss and
had to be stopped prematurely. This highlights the risks associated with the off-label use of drugs in newborn infants before safety assessment in controlled trials. Standardized, protocol-driven treatments improve consistency and short-term outcome in NSE and should be practiced at all centers keeping in mind the resource constraints.

**Fig. 1** Algorithmic approach to recurrent neonatal seizures. aEEG, amplitude-integrated EEG; EEG, electroencephalography; GC-MS, gas chromatography–mass spectrometry; MRI, magnetic resonance imaging; TMS, tandem mass spectrometry; USG, ultrasonography.
Outcomes

Although the immature brain is proposed to be more resistant to seizures and status-induced injury than an adult brain, several neurobiological changes such as disruption of neuronal development and networks, induction of synaptic reorganization, altered plasticity, molecular reorganization of receptors, and priming of the brain for secondary and tertiary injury has been reported.26 Status epilepticus has been shown to be an independent predictor of adverse neurological outcome and epilepsy at 2 years’ corrected age.2 The risk of development of epilepsy after early-life status epilepticus has been estimated at 13 to 74%.50 A relationship has been proposed between NSE and classic unilateral hippocampal sclerosis and temporal lobe epilepsy.51 The presence of status epilepticus significantly increases the odds for development of cerebral palsy, global developmental delay, and epilepsy.52 The effect of gestational age has not been significant on the outcomes.20,48 Febrile status epilepticus has been more frequently reported in children with a history of neonatal seizures and neurological abnormality.13

Conclusion

In conclusion, NSE is marker of neonatal brain injury and needs urgent evaluation, and the broad principles of management are extrapolated from guidelines for children and adults. As majority of NSEs are provoked, simultaneous treat- ment of the underlying etiology constitutes an important aspect of management. Further research is needed into the role of current antiepileptic drugs in causing neuronal injury and use of neuroprotective agents during NSE.

Funding

None.

Conflict of Interest

None.

References

29 Dlugos DJ. The nature of neonatal status epilepticus—a clinician’s perspective. Epilepsy Behav 2015;49:88–89
31 Saini AG, Taketani T, Sahu JK, Singh P. Startles, stiffness, and SLC6A5: do you know the condition? Pediatr Neurol 2018; 81:49–50
34 Clancy RR. Summary proceedings from the neurology group on neonatal seizures. Pediatrics 2006; 117(3 Pt 2):S23–S27
49 Akman O, Moshe SL, Galanopoulou AS. Early life status epilepticus and stress have distinct and sex-specific effects on learning, subsequent seizure outcomes, including anticonvulsant response to phenobarbital. CNS Neurosci Ther 2015; 21(2):181–192
50 Raspall-Charue M, Chin RF, Neville BG, Scott RC. Outcome of paediatric convulsive status epilepticus: a systematic review. Lancet Neurol 2006; 5(9):769–779